Please assess the completion status of the following clinical trial:

Trial Title: Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent or guardian can and will comply with the requirements of the protocol.~* A male or female between, and including, 1 through 10 years of age at the time of vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of his/her parents/guardians' knowledge.~Exclusion Criteria:~For the primary phase:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine(s).~* Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W, and/or Y (for subjects below 6 years) or within the last five previous years (for subjects 6 years old or above).~* Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W, and/or Y.~* Previous vaccination with tetanus toxoid containing vaccine within the last 28 days.~* History of meningococcal disease due to serogroup A, C, W, or Y.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~For the long term persistence phase:~* History of meningococcal serogroup A, C, W, and/or Y disease.~* Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine not planned in the protocol.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): All subjects received GSK Biolgicals' meningococcal vaccine 134612.
- Group B (Type: ACTIVE_COMPARATOR): Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete